The most probable hypothesis is that in the future, from next autumn, they will be used bivalent mRNA vaccines, that is, capable of acting both on the Wuhan stock and on the others. Preliminary data, explains the head of vaccine strategy of the European Medicines Agency Marco Cavaleriin fact show how this type of vaccines, incorporating a strain of the Omicron variant, are able to “increase and extend protectionwhen used as a booster ”
